Diffuse Large B-Cell Lymphoma, NOS · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | None |
| ID | IND-OCC-PCB-PREVENTION-INTENSIFIED-SURVEILLANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB — v0.3 IARC 2A probable-carcinogen batch (PCB; legacy 2A entry — reclassified to Group 1 in IARC Monograph 107, 2015). IARC Group 2A probable — limited human evidence; clinical recommendation more conservative than Group 1; reclassified Group 1 in 2013 IARC Monograph 107 (published 2015) — authored at 2A-conservative severity per batch scope. Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode exemption. No drug regimen — intervention is symptom-awareness + annual CBC + LDH + dermatologic + breast surveillance.
Used By
Red flag
RF-OCC-PCB-PREVENTION- Documented historical occupational exposure to polychlorinated biphenyls (PCBs) — typical...